Ralliant (NYSE:RAL) Director Anelise Angelino Sacks Buys 2,000 Shares

Ralliant Corporation (NYSE:RAL) Director Anelise Angelino Sacks bought 2,000 shares of the business’s stock in a transaction on Monday, February 9th. The shares were acquired at an average price of $41.25 per share, for a total transaction of $82,500.00. Following the completion of the purchase, the director owned 5,403 shares in the company, valued at approximately $222,873.75. The trade was a 58.77% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Ralliant Stock Up 4.7%

RAL stock opened at $43.11 on Wednesday. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $57.02. The business has a fifty day moving average price of $51.26 and a 200-day moving average price of $46.64. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 0.58. The stock has a market capitalization of $4.86 billion and a P/E ratio of 33.94.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.67 by $0.02. The business had revenue of $554.60 million for the quarter, compared to analysts’ expectations of $543.04 million. The firm’s revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant’s payout ratio is presently 15.75%.

Hedge Funds Weigh In On Ralliant

Institutional investors and hedge funds have recently bought and sold shares of the stock. Danske Bank A S purchased a new stake in Ralliant in the fourth quarter worth about $25,000. Westfuller Advisors LLC bought a new position in shares of Ralliant during the 3rd quarter valued at approximately $26,000. V Square Quantitative Management LLC bought a new position in shares of Ralliant during the 4th quarter valued at approximately $26,000. Allworth Financial LP increased its holdings in Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after acquiring an additional 293 shares in the last quarter. Finally, Palisade Asset Management LLC bought a new stake in Ralliant during the 3rd quarter worth approximately $26,000.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RAL. Oppenheimer lowered their price target on Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday. Royal Bank Of Canada cut their price objective on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday. Barclays lowered their target price on Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a report on Monday. Citigroup dropped their target price on Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Finally, Weiss Ratings lowered shares of Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research report on Thursday, February 5th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Ralliant currently has an average rating of “Moderate Buy” and a consensus price target of $50.50.

Ralliant News Summary

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Multiple insider purchases (SVP Amir Kazmi, Director Kevin Bryant and others) signal management confidence and provide a buy signal to some investors. Read More. Read More.
• Positive Sentiment: Research upgrades (Vertical Research upgraded RAL) can attract buyers and support near‑term demand. Read More.
• Neutral Sentiment: Barclays lowered its price target (from $60 to $52) but kept an Overweight rating — still implies upside but reduces near‑term enthusiasm. Read More.
• Neutral Sentiment: Citigroup trimmed its target to $51 — a modest negative to sentiment but still above current trading levels. Read More.
• Negative Sentiment: Ralliant reported a $1.4 billion non‑cash goodwill impairment in its Test & Measurement segment and reduced FY2026 outlook — a substantive charge that led to analyst re‑ratings and is a key fundamental negative. Read More.
• Negative Sentiment: Multiple law firms (including Levi & Korsinsky, Kessler Topaz, Kirby McInerney, Bragar Eagel & Squire and Kaplan Fox) have opened or publicized investigations into potential securities‑law violations tied to the timing and disclosure of the impairment and guidance — this raises regulatory, litigation and reputational risk. Read More.
• Negative Sentiment: Short interest jumped ~58.7% in January to ~3.75M shares (about 3.3% of float) — increased bearish positioning can amplify downside pressure and intraday volatility.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.